cas 1118767-15-9|| where to buy tert-butyl 18-[[(2S)-5-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-[(2-methylpropan-2-yl)oxy]-1,5-dioxopentan-2-yl]amino]-18-oxooctadecanoate

Nom du produit:tert-butyl 18-[[(2S)-5-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-[(2-methylpropan-2-yl)oxy]-1,5-dioxopentan-2-yl]amino]-18-oxooctadecanoate

IUPAC Name:tert-butyl 17-{[(2S)-1-(tert-butoxy)-4-({2-[2-({[2-(2-{2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethoxy}ethoxy)ethyl]carbamoyl}methoxy)ethoxy]ethyl}carbamoyl)-1-oxobutan-2-yl]carbamoyl}heptadecanoate

: CAS：1118767-15-9; Formule moléculaire：C47H82N4O15; Pureté：95%+

: Numéro de catalogue：CM590183; Poids moléculaire：943.19

Unité d'emballage	Stock disponible	Prix($)
CM590183-100mg	in stock	ƩǠ
CM590183-250mg	in stock	ƻșș
CM590183-1g	in stock	ŭǺǠ
CM590183-5g	in stock	Ǡƅƻ

Demande: sales@chemenu.com

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1118767-15-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

Détails du produit

: N° CAS:1118767-15-9; Formule moléculaire:C47H82N4O15; Point de fusion:-; Code SMILES:CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)ON1C(=O)CCC1=O)C(=O)OC(C)(C)C; Densité:

: Numéro de catalogue:CM590183; Poids moléculaire:943.19; Point d'ébullition:; N° Mdl:; Stockage:

Category Infos

: Fatty Acid Modified Side Chains; Fatty acid-modified side chains are small molecule modifiers and are one of the important factors that change the pharmacokinetic behavior of insulin products. Peptide drugs have the problem of short half-life and easy degradation in clinical practice. Introducing fatty acid-modified side chains into peptide drugs can increase the hydrophobicity of the drug and increase the biological half-life, thereby reducing the dosage and frequency of medication.